June 22, 2018
On 22 June 2018, Janssen issued a Dear Doctor letter (linked below) against using darunavir/cobicistat during pregnancy.1
This new contraindication is based on significantly reduced plasma levels of darunavir and cobicistat during the second and third trimesters of pregnancy.
Darunavir can still be used during pregnancy, but only when boosted by ritonavir
The new results are from a pharmacokinetic study presented earlier this year in six HIV positive pregnant women and a more recent FDA update.2,3
In summary, the mean exposure (AUC) of darunavir boosted with cobicistat was 56% and 50% lower during the second and third trimesters of pregnancy, respectively, compared with 6 to 12 weeks postpartum. Mean darunavir Cmin concentrations were around 90% lower during the second and third trimesters, compared to postpartum. Exposure of cobicistat was 63% and 49% lower during the second and third trimeters, respectively, as compared to postpartum.
Although another recent FDA update to the darunavir/cobicistat in February 2018 cautioned about low darunavir exposure during the third trimester, the new alert goes further in making pregnancy a contraindication.4
No HIV transmissions to the baby were reported in these studies, but it is unclear whether transmissions have been reported in other settings.
The coformulation of darunavir/cobicisat is marketed as Rezolsta in the EU and Prezcobix in the US.
The single pill fixed dose combination of darunavir/cobicistat/emtricitabine/TAF is marketed as Symtuza.
[Note from TheBodyPRO: This article was originally published by HIV i-Base on June 22, 2018. We have cross-posted it with their permission.]
|Research Is Still Exploring Best Treatment Strategies for Pregnant and Breastfeeding Women, Interactions With Contraceptives|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.